NasdaqCM - Nasdaq Real Time Price
USD
Corcept Therapeutics Incorporated (CORT)
81.12
-4.83
(-5.62%)
At close: 4:00:01 PM EDT
81.12
0.00
(0.00%)
After hours: 4:00:16 PM EDT
Trade CORT on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for CORT
What's happening with CORT?
Powered by Yahoo ScoutCorcept Therapeutics is entering a key reporting period after positive Phase 2 BELLA results for Lifyorli in platinum-resistant ovarian cancer. The company also faces near-term catalysts from its November 3, 2026 earnings updateand a potential December 2026 FDA decisionon relacorilant for Cushing’s syndrome. The current session shows CORT down 5.62%.
Powered by Yahoo Scout
- Previous Close
85.95 - Open
84.87 - Bid 73.77 x 200
- Ask 86.76 x 200
- Day's Range
80.28 - 85.31 - 52 Week Range
28.66 - 126.38 - Volume
1,425,918 - Avg. Volume
1,175,804 - Market Cap (intraday)
8.769B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
180.27 - EPS (TTM)
0.45 - Earnings Date Nov 3, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
141.00 - Zacks Rating Neutral
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CORT
133.10%
S&P 500 (^GSPC)
10.73%
1-Year Return
CORT
12.26%
S&P 500 (^GSPC)
11.11%
3-Year Return
CORT
196.82%
S&P 500 (^GSPC)
81.91%
5-Year Return
CORT
350.67%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/29/2026
-
Market Cap
9.30B
-
Enterprise Value
9.00B
-
Trailing P/E
191.09
-
Forward P/E
15.25
-
PEG Ratio (current)
53.58
-
Price/Sales (ttm)
12.22
-
Price/Book (mrq)
13.15
-
Enterprise Value/Revenue
10.83
-
Enterprise Value/EBITDA
1.02k
Financial Highlights
Profitability and Income Statement
-
Profit Margin
6.64%
-
Return on Assets (ttm)
0.47%
-
Return on Equity (ttm)
8.23%
-
Revenue (ttm)
830.81M
-
Net Income Avi to Common (ttm)
54.27M
-
Diluted EPS (ttm)
0.45
Balance Sheet and Cash Flow
-
Total Cash (mrq)
308.2M
-
Total Debt/Equity (mrq)
1.34%
-
Levered Free Cash Flow (ttm)
77.4M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap
undefined
-
Industry
-
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Lowering target price to $92.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $92.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
-
Lowering target price to $122.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $122.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
-
Lowering target price to $124.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $124.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
-
Raising target price to $126.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $126.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
